Phage Therapy: A Different Approach to Fight Bacterial Infections

References

• Danis-Wlodarczyk K, Dąbrowska K, Abedon ST. Phage therapy: the pharmacology of antibacterial viruses. Curr Issues Mol Biol. 2020;40:81–164. doi:10.21775/cimb.040.081
   PubMed Web of Science ®Google Scholar
• Hendrix RW. Bacteriophages: evolution of the majority. Theor Popul Biol. 2002;61(4):471–480. doi:10.1006/tpbi.2002.1590
   PubMed Web of Science ®Google Scholar
• Sabour PM, Griffiths MW. Bacteriophages in the Control of Food-and Waterborne Pathogens. American Society for Microbiology Press; 2010.
   Google Scholar
• Servick K. Beleaguered phage therapy trial presses on. American Association for the Advancement of Science; 2016.
   Google Scholar
• Viertel TM, Ritter K, Horz H-P. Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother. 2014;69(9):2326–2336. doi:10.1093/jac/dku173
   PubMed Web of Science ®Google Scholar
• Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162. doi:10.4292/wjgpt.v8.i3.162
   PubMedGoogle Scholar
• Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. Viruses. 2019;11(1):18. doi:10.3390/v11010018
   Web of Science ®Google Scholar
• Love MJ, Bhandari D, Dobson RC, Billington C. Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care. Antibiotics. 2018;7(1):17. doi:10.3390/antibiotics7010017
   Web of Science ®Google Scholar
• Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B. Bacteriophages and phage-derived proteins–application approaches. Curr Med Chem. 2015;22(14):1757–1773. doi:10.2174/0929867322666150209152851
   PubMed Web of Science ®Google Scholar
• Hobbs Z, Abedon ST, Millard A. Diversity of phage infection types and associated terminology: the problem with ‘Lytic or lysogenic’. FEMS Microbiol Lett. 2016;363(7):fnw047. doi:10.1093/femsle/fnw047
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang L, Yang D, et al. Specific integration of temperate phage decreases the pathogenicity of host bacteria. Front Cell Infect Microbiol. 2020;10:14. doi:10.3389/fcimb.2020.00014
   PubMed Web of Science ®Google Scholar
• Örmälä A-M, Jalasvuori M. Phage therapy: should bacterial resistance to phages be a concern even in the long run?. Bacteriophage. 2013;3(1):e24219. doi:10.4161/bact.24219
   PubMedGoogle Scholar
• Brives C, Pourraz J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun. 2020;6(1):1–11. doi:10.1057/s41599-020-0478-4
   Web of Science ®Google Scholar
• Reuter M, Kruger DH. Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections. Virus Genes. 2020;56(2)1–14.
   PubMed Web of Science ®Google Scholar
• Romero-Calle D, Benevides RG, Góes-Neto A, Billington C. Bacteriophages as alternatives to antibiotics in clinical care. Antibiotics. 2019;8(3):138. doi:10.3390/antibiotics8030138
   Web of Science ®Google Scholar
• Pirnay J-P. Phage therapy in the year 2035. Front Microbiol. 2020;11:1171. doi:10.3389/fmicb.2020.01171
   PubMed Web of Science ®Google Scholar
• Jończyk-Matysiak E, Weber-Dąbrowska B, Owczarek B. Phage-phagocyte interactions and their implications for phage application as therapeutics. Viruses. 2017;9(6):150. doi:10.3390/v9060150
   PubMed Web of Science ®Google Scholar
• Górski A, Dąbrowska K, Międzybrodzki R. Phages and immunomodulation. Future Microbiol. 2017;12(10):905–914. doi:10.2217/fmb-2017-0049
   PubMed Web of Science ®Google Scholar
• Krut O, Bekeredjian-Ding I. Contribution of the immune response to phage therapy. J Immunol. 2018;200(9):3037–3044. doi:10.4049/jimmunol.1701745
   PubMed Web of Science ®Google Scholar
• Cafora M, Brix A, Forti F, et al. Phages as immunomodulators and their promising use as anti-inflammatory agents in a CFTR loss-of-function zebrafish model. J Cyst Fibros. 2021;20(6):1046–1052. doi:10.1016/j.jcf.2020.11.017
   PubMed Web of Science ®Google Scholar
• Hashiguchi S, Yamaguchi Y, Takeuchi O, Akira S, Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling. Biochem Biophys Res Commun. 2010;402(1):19–22. doi:10.1016/j.bbrc.2010.09.094
   PubMed Web of Science ®Google Scholar
• Dąbrowska K, Miernikiewicz P, Piotrowicz A. Immunogenicity studies of proteins forming the T4 phage head surface. J Virol. 2014;88(21):12551–12557. doi:10.1128/JVI.02043-14
   PubMed Web of Science ®Google Scholar
• Van Belleghem JD, Vaneechoutte M, Barr JJ, Bollyky PL, Bollyky P. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses. 2018;11(1):10. doi:10.3390/v11010010
   PubMed Web of Science ®Google Scholar
• Gã³rski A, Miä™dzybrodzki R, Borysowski J, et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res. 2012;83:41–71.
   PubMed Web of Science ®Google Scholar
• Szermer-Olearnik B, Boratyå„ski J, Skurnik M. Removal of endotoxins from bacteriophage preparations by extraction with organic solvents. PLoS One. 2015;10(3):e0122672. doi:10.1371/journal.pone.0122672
   PubMed Web of Science ®Google Scholar
• Leung CYJ, Weitz JS. Modeling the synergistic elimination of bacteria by phage and the innate immune system. J Theor Biol. 2017;429:241–252. doi:10.1016/j.jtbi.2017.06.037
   PubMed Web of Science ®Google Scholar
• Wang J, Hu B, Xu M, et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum β-lactamase-producing Escherichia coli bacteremia. Int J Mol Med. 2006;17(2):347–355.
   PubMed Web of Science ®Google Scholar
• Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002;70(1):204–210. doi:10.1128/IAI.70.1.204-210.2002
   PubMed Web of Science ®Google Scholar
• Hodyra-Stefaniak K, Miernikiewicz P, Drapała J. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5(1):1–13. doi:10.1038/srep14802
   Web of Science ®Google Scholar
• Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8(5):317–327. doi:10.1038/nrmicro2315
   PubMed Web of Science ®Google Scholar
• Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020;44(6):684–700. doi:10.1093/femsre/fuaa017
   PubMed Web of Science ®Google Scholar
• Weissman JL, Holmes R, Barrangou R, et al. Immune loss as a driver of coexistence during host-phage coevolution. ISME J. 2018;12(2):585–597. doi:10.1038/ismej.2017.194
   PubMed Web of Science ®Google Scholar
• Koskella B, Brockhurst MA. Bacteria–phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev. 2014;38(5):916–931. doi:10.1111/1574-6976.12072
   PubMed Web of Science ®Google Scholar
• Azam AH, Tanji Y. Bacteriophage-host arm race: an update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy. Appl Microbiol Biotechnol. 2019;103(5):2121–2131. doi:10.1007/s00253-019-09629-x
   PubMed Web of Science ®Google Scholar
• Burmeister AR, Turner PE. Trading-off and trading-up in the world of bacteria–phage evolution. Current Biol. 2020;30(19):R1120–R1124. doi:10.1016/j.cub.2020.07.036
   PubMed Web of Science ®Google Scholar
• Vasu K, Nagaraja V. Diverse functions of restriction-modification systems in addition to cellular defense. Microbiol Mol Biol Rev. 2013;77(1):53–72. doi:10.1128/MMBR.00044-12
   PubMed Web of Science ®Google Scholar
• Dryden D. S-Adenosylmethionine-Dependent Methyltransferases: Structures and Functions. Bacterial DNA Methyltransferases. Singapore: World Scientific Publishing; 1999:283–340.
   Google Scholar
• Bonsma-Fisher M, Soutière D, Goyal S. How adaptive immunity constrains the composition and fate of large bacterial populations. Proc Natl Acad Sci. 2018;115(32):E7462–E7468. doi:10.1073/pnas.1802887115
   PubMed Web of Science ®Google Scholar
• Bennett P. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. Br J Pharmacol. 2008;153(S1):S347–S57. doi:10.1038/sj.bjp.0707607
   PubMed Web of Science ®Google Scholar
• Dahlberg C, Chao L. Amelioration of the cost of conjugative plasmid carriage in Escherichia coli K12. Genetics. 2003;165(4):1641–1649. doi:10.1093/genetics/165.4.1641
   PubMed Web of Science ®Google Scholar
• Dionisio F, Conceicao I, Marques A, Fernandes L, Gordo I. The evolution of a conjugative plasmid and its ability to increase bacterial fitness. Biol Lett. 2005;1(2):250–252. doi:10.1098/rsbl.2004.0275
   PubMed Web of Science ®Google Scholar
• Malone LM, Birkholz N, Fineran PC. Conquering CRISPR: how phages overcome bacterial adaptive immunity. Curr Opin Biotechnol. 2020;68:30–36. doi:10.1016/j.copbio.2020.09.008
   PubMed Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–1712. doi:10.1126/science.1138140
   PubMed Web of Science ®Google Scholar
• Deveau H, Barrangou R, Garneau JE, et al. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2008;190(4):1390–1400. doi:10.1128/JB.01412-07
   PubMed Web of Science ®Google Scholar
• Semenova E, Jore MM, Datsenko KA, et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci. 2011;108(25):10098–10103. doi:10.1073/pnas.1104144108
   PubMed Web of Science ®Google Scholar
• Shearer WT, Lugg DJ, Rosenblatt HM, et al. Antibody responses to bacteriophage φX-174 in human subjects exposed to the Antarctic winter-over model of spaceflight. J Allergy Clin Immunol. 2001;107(1):160–164. doi:10.1067/mai.2001.112269
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Mizrachi Y, Bernstein L, et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage φX174 in asymptomatic HIV-1 infected patients. AIDS. 2000;14(4):F55–F62. doi:10.1097/00002030-200003100-00004
   PubMed Web of Science ®Google Scholar
• Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E. Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system. Nat Commun. 2012;3(1):1–7. doi:10.1038/ncomms1937
   Web of Science ®Google Scholar
• Swarts DC, Mosterd C, Van Passel MW, Brouns SJ, Mokrousov I. CRISPR interference directs strand specific spacer acquisition. PLoS One. 2012;7(4):e35888. doi:10.1371/journal.pone.0035888
   PubMed Web of Science ®Google Scholar
• Pyenson NC, Gayvert K, Varble A, Elemento O, Marraffini LA. Broad targeting specificity during bacterial type III CRISPR-Cas immunity constrains viral escape. Cell Host Microbe. 2017;22(3):343–53. e3. doi:10.1016/j.chom.2017.07.016
   PubMed Web of Science ®Google Scholar
• Marino ND, Pinilla-Redondo R, Csörgő B, Bondy-Denomy J. Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies. Nat Methods. 2020;17(5):471–479. doi:10.1038/s41592-020-0771-6
   PubMed Web of Science ®Google Scholar
• Wiegand T, Karambelkar S, Bondy-Denomy J, Wiedenheft B. Structures and strategies of anti-CRISPR-mediated immune suppression. Annu Rev Microbiol. 2020;74:21–37. doi:10.1146/annurev-micro-020518-120107
   PubMed Web of Science ®Google Scholar
• Patterson AG, Yevstigneyeva MS, Fineran PC. Regulation of CRISPR–Cas adaptive immune systems. Curr Opin Microbiol. 2017;37:1–7. doi:10.1016/j.mib.2017.02.004
   PubMed Web of Science ®Google Scholar
• Borges AL, Castro B, Govindarajan S, Solvik T, Escalante V, Bondy-Denomy J. Bacterial alginate regulators and phage homologs repress CRISPR–Cas immunity. Nature Microbiol. 2020;5(5):679–687. doi:10.1038/s41564-020-0691-3
   PubMed Web of Science ®Google Scholar
• Hargreaves KR, Kropinski AM, Clokie MR. Bacteriophage behavioral ecology: how phages alter their bacterial host’s habits. Bacteriophage. 2014;4(3):e85131. doi:10.4161/bact.29866
   Google Scholar
• Patterson AG, Jackson SA, Taylor C, et al. Quorum sensing controls adaptive immunity through the regulation of multiple CRISPR-Cas systems. Mol Cell. 2016;64(6):1102–1108. doi:10.1016/j.molcel.2016.11.012
   PubMed Web of Science ®Google Scholar
• Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature. 2013;493(7432):429–432. doi:10.1038/nature11723
   PubMed Web of Science ®Google Scholar
• Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10(7):351. doi:10.3390/v10070351
   PubMed Web of Science ®Google Scholar
• Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769–783. doi:10.2217/fmb.13.47
   PubMed Web of Science ®Google Scholar
• Pirnay J-P, De Vos D, Verbeken G, et al. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res. 2011;28(4):934–937. doi:10.1007/s11095-010-0313-5
   PubMed Web of Science ®Google Scholar
• Górski A, Międzybrodzki R, Weber-Dąbrowska B, et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515. doi:10.3389/fmicb.2016.01515
   PubMed Web of Science ®Google Scholar
• Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci. 2007;104(27):11197–11202. doi:10.1073/pnas.0704624104
   PubMed Web of Science ®Google Scholar
• Tinoco JM, Buttaro B, Zhang H, Liss N, Sassone L, Stevens R. Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms. Arch Oral Biol. 2016;71:80–86. doi:10.1016/j.archoralbio.2016.07.001
   PubMed Web of Science ®Google Scholar
• Tinoco JM, Buttaro B, Zhang H, Liss N, Sassone L, Stevens R. Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms. Arch Oral Biol. 2019;71:80–86.
   Web of Science ®Google Scholar
• Monteiro R, Pires DP, Costa AR, Azeredo J. Phage therapy: going temperate? Trends Microbiol. 2019;27(4):368–378. doi:10.1016/j.tim.2018.10.008
   PubMed Web of Science ®Google Scholar
• Ando H, Lemire S, Pires DP, Lu TK. Engineering modular viral scaffolds for targeted bacterial population editing. Cell Systems. 2015;1(3):187–196. doi:10.1016/j.cels.2015.08.013
   PubMed Web of Science ®Google Scholar
• Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci. 2009;106(12):4629–4634. doi:10.1073/pnas.0800442106
   PubMed Web of Science ®Google Scholar
• Yacoby I, Bar H, Benhar I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob Agents Chemother. 2007;51(6):2156–2163. doi:10.1128/AAC.00163-07
   PubMed Web of Science ®Google Scholar
• Russel M, Linderoth NA, Šali A. Filamentous phage assembly: variation on a protein export theme. Gene. 1997;192(1):23–32. doi:10.1016/S0378-1119(96)00801-3
   PubMed Web of Science ®Google Scholar
• Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219–232. doi:10.1016/j.chom.2019.01.014
   PubMed Web of Science ®Google Scholar
• Wang N, Deaton J, Young R. Sizing the holin lesion with an endolysin-β-galactosidase fusion. J Bacteriol. 2003;185(3):779–787. doi:10.1128/JB.185.3.779-787.2003
   PubMed Web of Science ®Google Scholar
• Jervis EJ, Guarna MM, Doheny JG, Haynes CA, Kilburn DG. Dynamic localization and persistent stimulation of factor‐dependent cells by a stem cell factor/cellulose binding domain fusion protein. Biotechnol Bioeng. 2005;91(3):314–324. doi:10.1002/bit.20611
   PubMed Web of Science ®Google Scholar
• Adhya S, Merril CR, Biswas B. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harb Perspect Med. 2014;4(1):a012518. doi:10.1101/cshperspect.a012518
   PubMed Web of Science ®Google Scholar
• Lukacik P, Barnard TJ, Keller PW, et al. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci. 2012;109(25):9857–9862. doi:10.1073/pnas.1203472109
   PubMed Web of Science ®Google Scholar
• Yosef I, Kiro R, Molshanski-Mor S, Edgar R, Qimron U. Different approaches for using bacteriophages against antibiotic-resistant bacteria. Bacteriophage. 2014;4(1):19549–19554. doi:10.4161/bact.28491
   Google Scholar
• Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015;5(3):e1062590. doi:10.1080/21597081.2015.1062590
   PubMedGoogle Scholar
• Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci. 2015;112(23):7267–7272. doi:10.1073/pnas.1500107112
   PubMed Web of Science ®Google Scholar
• Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5(1):1–13.
   Web of Science ®Google Scholar
• Chopra S, Harjai K, Chhibber S. Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. Int J Med Microbiol. 2016;306(8):707–716. doi:10.1016/j.ijmm.2016.08.003
   PubMed Web of Science ®Google Scholar
• Wittekind M, Schuch R. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. Curr Opin Microbiol. 2016;33:18–24. doi:10.1016/j.mib.2016.05.006
   PubMed Web of Science ®Google Scholar
• Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018;8:376. doi:10.3389/fcimb.2018.00376
   PubMed Web of Science ®Google Scholar
• Harper DR. Criteria for selecting suitable infectious diseases for phage therapy. Viruses. 2018;10(4):177. doi:10.3390/v10040177
   PubMed Web of Science ®Google Scholar
• de Jonge PA, Nobrega FL, Brouns SJ, Dutilh BE. Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 2018;27(1):51–63. doi:10.1016/j.tim.2018.08.006
   PubMed Web of Science ®Google Scholar
• Payne RJ, Jansen VA. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42(4):315–325. doi:10.2165/00003088-200342040-00002
   PubMed Web of Science ®Google Scholar
• Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR. The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genetic Med. 2012;6:279. doi:10.4172/1747-0862.1000050
   PubMedGoogle Scholar
• Speck P, Smithyman A, Millard A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett. 2016;363(3):fnv242. doi:10.1093/femsle/fnv242
   PubMed Web of Science ®Google Scholar
• Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11(1):69–86. doi:10.2174/138920110790725401
   PubMed Web of Science ®Google Scholar
• Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237–243. doi:10.12968/jowc.2009.18.6.42801
   PubMedGoogle Scholar
• Wright A, Hawkins C, Änggã¥rd E, Harper D. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin otolaryngol. 2009;34(4):349–357. doi:10.1111/j.1749-4486.2009.01973.x
   PubMed Web of Science ®Google Scholar
• Abd El-Baky RM, Ibrahim RA, Mohamed DS, Ahmed EF, Hashem ZS. Prevalence of virulence genes and their association with antimicrobial resistance among pathogenic E. coli isolated from Egyptian patients with different clinical infections. Infect Drug Resist. 2020;13:1221. doi:10.2147/IDR.S241073
   PubMed Web of Science ®Google Scholar
• Yang J, Chen L, Sun L, Yu J, Jin Q. VFDB 2008 release: an enhanced web-based resource for comparative pathogenomics. Nucleic Acids Res. 2007;36(suppl_1):D539–D542. doi:10.1093/nar/gkm951
   PubMed Web of Science ®Google Scholar
• Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012;434(2):222–232. doi:10.1016/j.virol.2012.09.002
   PubMed Web of Science ®Google Scholar
• Muniesa M, Imamovic L, Jofre J. Bacteriophages and genetic mobilization in sewage and faecally polluted environments. Microb Biotechnol. 2011;4(6):725–734. doi:10.1111/j.1751-7915.2011.00264.x
   PubMed Web of Science ®Google Scholar
• Divya Ganeshan S, Hosseinidoust Z. Phage therapy with a focus on the human microbiota. Antibiotics. 2019;8(3):131. doi:10.3390/antibiotics8030131
   Web of Science ®Google Scholar
• Santos S, Fernandes E, Carvalho CM, et al. Selection and characterization of a multivalent Salmonella phage and its production in a nonpathogenic Escherichia coli strain. Appl Environ Microbiol. 2010;76(21):7338–7342. doi:10.1128/AEM.00922-10
   PubMed Web of Science ®Google Scholar
• Mutti M, Corsini L, Zhou H. Robust approaches for the production of active ingredient and drug product for human phage therapy. Front Microbiol. 2019;10:10. doi:10.3389/fmicb.2019.00010
   PubMed Web of Science ®Google Scholar
• Pirnay J-P, Blasdel BG, Bretaudeau L, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res. 2015;32(7):2173–2179. doi:10.1007/s11095-014-1617-7
   PubMed Web of Science ®Google Scholar
• Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Ann rev virol. 2015;2:599–618. doi:10.1146/annurev-virology-100114-054915
   PubMed Web of Science ®Google Scholar
• Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11(1):2–14. doi:10.2174/138920110790725311
   PubMed Web of Science ®Google Scholar
• Ackermann H-W, Tremblay D, Moineau S. Long-term bacteriophage preservation; 2004.
   Google Scholar
• Tovkach F, Zhuminska G, Kushkina A. Long-term preservation of unstable bacteriophages of enterobacteria. Mikrobiol Z. 2012;74(2):60–66.
   PubMedGoogle Scholar
• Jończyk E, Kłak M, Międzybrodzki R, Górski A. The influence of external factors on bacteriophages. Folia Microbiol. 2011;56(3):191–200. doi:10.1007/s12223-011-0039-8
   PubMed Web of Science ®Google Scholar
• Pires DP, Boas DV, Sillankorva S, Azeredo J, Goff SP. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol. 2015;89(15):7449–7456. doi:10.1128/JVI.00385-15
   PubMed Web of Science ®Google Scholar
• Adesanya O, Oduselu T, Akin-Ajani O, Adewumi OM, Ademowo OG. An exegesis of bacteriophage therapy: an emerging player in the fight against anti-microbial resistance. AIMS Microbiol. 2014;6(3):204. doi:10.3934/microbiol.2020014
   Web of Science ®Google Scholar